Back

Long-term management of patients with ATTR-CM.

22 May 2022 (15:15 - 15:30)
Organised by:
Congress Presentation Part of: Looking beyond heart failure: could it be transthyretin amyloid cardiomyopathy (ATTR-CM)? Cardiac Diseases Open Access Heart Failure 2022

About the speaker

Photo
Professor Claudio Rapezzi

University of Ferrara, Ferrara (Italy)

3 More presentations in this session

Presentation thumbnail
Heart failure or ATTR-CM? The importance of early diagnosis.
Doctor J. Gonzalez-Costello (Hospitalet De Llobregat, ES)
Presentation thumbnail
Clinical perspectives: raising suspicion and diagnosing ATTR-CM in patients with heart failure.
Associate Professor A. Pollak (Jerusalem, IL)
Slides Video
Presentation thumbnail
Panel discussion and Q&A.
Slides Video

Access the full session

Session thumbnail
Looking beyond heart failure: could it be transthyretin amyloid cardiomyopathy (ATTR-CM)?

The Event

Event poster

Heart Failure 2022

22 May 2022 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Long term treatment with tafamidis in ATTR-CM: 7.5 year outcomes from the phase 3 open label long-term extension study
11 May 2026
thumbnail
Congress Presentation
Currently available therapies: which results? which indications?
13 May 2024
thumbnail
Congress Presentation
Perspectives on current & future pharmacological treatments of transthyretin amyloid cardiomyopathy (ATTR-CM)
28 August 2023
thumbnail
Congress Session
Transthyretin amyloidosis: long-term outcomes and emerging therapies
11 May 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources